Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q1 2024 · 10-Q
Revenue$16.60M$16.60M+39.4% vs Q1 2023 Net Income-$5.66M-$5.66MN/M vs Q1 2023 EPS Diluted-$0.23-$0.23N/M vs Q1 2023 Gross Profit$11,336,000+43.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Operating Cash Flow-$14,384,000N/M Free Cash Flowderived-$14,688,000N/M Margins · derivedGross margin68.3%+2.0 pt vs Q1 2023
Operating margin-29.1%+65.4 pt vs Q1 2023
Net margin-34.1%+66.9 pt vs Q1 2023
ended Mar 31, 2024 · filed May 10, 2024 · 40 d after period end